-
公开(公告)号：US06288082B1
公开(公告)日：2001-09-11
申请号：US09406573
申请日：1999-09-24
申请人： Allan Wissner , Hwei-Ru Tsou , Dan M. Berger , Middleton B. Floyd, Jr. , Philip R. Hamann , Nan Zhang , Mark E. Salvati , Philip Frost
发明人： Allan Wissner , Hwei-Ru Tsou , Dan M. Berger , Middleton B. Floyd, Jr. , Philip R. Hamann , Nan Zhang , Mark E. Salvati , Philip Frost
IPC分类号： A61K3147
CPC分类号： C07D401/12 , C07D215/48 , C07D417/12
摘要： This invention provides compounds of formula I having the structure wherein G1, G2, R1, R4, Z, n, and X are defined in the specification or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.
-
公开(公告)号：US06297258B1
公开(公告)日：2001-10-02
申请号：US09630270
申请日：2000-08-01
申请人： Allan Wissner , Hwei-Ru Tsou , Dan M. Berger , Middleton B. Floyd, Jr. , Philip R. Hamann , Nan Zhang , Philip Frost
发明人： Allan Wissner , Hwei-Ru Tsou , Dan M. Berger , Middleton B. Floyd, Jr. , Philip R. Hamann , Nan Zhang , Philip Frost
IPC分类号： A61K3147
CPC分类号： C07D215/54 , C07D215/44 , C07D215/56
摘要： This invention provides compounds of formula I having the structure wherein G1, G2, R1, R4, Z, n, and X are defined in the specification or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.
摘要翻译： 本发明提供了具有其结构的式I化合物，其中G1，G2，R1，R4，Z，n和X在本说明书或其药学上可接受的盐中定义，其可用作抗肿瘤药物和治疗多囊肾病。
-
公开(公告)号：USRE42376E1
公开(公告)日：2011-05-17
申请号：US12785269
申请日：2010-05-21
申请人： Allan Wissner , Hwei-Ru Tsou , Dan M. Berger , Middleton B. Floyd, Jr. , Philip R. Hamann , Nan Zhang , Philip Frost
发明人： Allan Wissner , Hwei-Ru Tsou , Dan M. Berger , Middleton B. Floyd, Jr. , Philip R. Hamann , Nan Zhang , Philip Frost
IPC分类号： A61K31/47 , C07D215/44
CPC分类号： C07D215/54 , C07D215/44 , C07D215/56
摘要： This invention provides compounds of formula I having the structure wherein G1, G2, R1, R4, Z, n, and X are defined in the specification or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.
摘要翻译： 本发明提供具有以下结构的式I化合物：其中G1，G2，R1，R4，Z，n和X在本说明书中定义，或其药学上可接受的盐，其可用作抗肿瘤剂和治疗多囊肾病 。
-
公开(公告)号：US06638929B2
公开(公告)日：2003-10-28
申请号：US09751274
申请日：2000-12-29
申请人： Dan M. Berger , Minu D. Dutia , Frenel F. DeMorin , Diane H. Boschelli , Dennis W. Powell , Hwei-Ru Tsou , Allan Wissner , Nan Zhang , Fei Ye , Biqi Wu
发明人： Dan M. Berger , Minu D. Dutia , Frenel F. DeMorin , Diane H. Boschelli , Dennis W. Powell , Hwei-Ru Tsou , Allan Wissner , Nan Zhang , Fei Ye , Biqi Wu
IPC分类号： A61K31535
CPC分类号： C07D401/12 , C07D215/48 , C07D215/54 , C07D215/56 , C07D219/04 , C07D219/06 , C07D219/08 , C07D221/08 , C07D333/66 , C07D333/70 , C07D401/14 , C07D471/04 , C07D491/04 , C07D495/04 , C07D513/04 , C07F7/0812
摘要： This invention provides compounds of formula 1, having the structure which are useful as inhibitors of protein tyrosine kinase and are antiproliferative agents.
摘要翻译： 本发明提供式1化合物，其具有可用作蛋白酪氨酸激酶抑制剂的结构，并且是抗增殖剂。
-
公开(公告)号：US07105531B2
公开(公告)日：2006-09-12
申请号：US10618044
申请日：2003-07-10
申请人： Dan M. Berger , Minu D. Dutia , Frenel F. DeMorin , Diane H. Boschelli , Dennis W. Powell , Hwei-Ru Tsou , Allan Wissner , Nan Zhang , Fei Ye , Biqi Wu
发明人： Dan M. Berger , Minu D. Dutia , Frenel F. DeMorin , Diane H. Boschelli , Dennis W. Powell , Hwei-Ru Tsou , Allan Wissner , Nan Zhang , Fei Ye , Biqi Wu
IPC分类号： A61K31/44 , C07D471/04
CPC分类号： C07D401/12 , C07D215/48 , C07D215/54 , C07D215/56 , C07D219/04 , C07D219/06 , C07D219/08 , C07D221/08 , C07D333/66 , C07D333/70 , C07D401/14 , C07D471/04 , C07D491/04 , C07D495/04 , C07D513/04 , C07F7/0812
摘要： This invention provides compounds of formula 1, having the structure which are useful as inhibitors of protein tyrosine kinase and are antiproliferative agents.
摘要翻译： 本发明提供式1化合物，其具有可用作蛋白酪氨酸激酶抑制剂的结构，并且是抗增殖剂。
-
公开(公告)号：US5639887A
公开(公告)日：1997-06-17
申请号：US450172
申请日：1995-05-25
申请人： Dennis Powell , Rolf Paul , William A. Hallett , Dan M. Berger , Minu D. Dutia
发明人： Dennis Powell , Rolf Paul , William A. Hallett , Dan M. Berger , Minu D. Dutia
IPC分类号： A61K31/40 , A61K31/403 , A61K31/4035 , A61K31/47 , A61K31/472 , A61K45/00 , A61P35/00 , A61P43/00 , C07C323/07 , C07C323/16 , C07C323/56 , C07C323/60 , C07D209/44 , C07D209/48 , C07D215/20 , C07D217/02 , C07D217/04 , C07D217/06 , C07D217/20 , C07D217/24 , C07D401/12 , C07D405/06 , C07D491/04 , C07D491/056 , C07D521/00 , C07F7/10 , C07F7/18 , C07D211/72 , C07D309/00
CPC分类号： C07D209/48 , C07C323/07 , C07C323/16 , C07C323/56 , C07C323/60 , C07D209/44 , C07D217/02 , C07D217/04 , C07D217/06 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D405/06 , C07D491/04 , C07F7/1856 , C07C2101/14
摘要： Compounds of the general formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are herein described, A is a straight or branched (C.sub.2 -C.sub.12)alkyl or a phenyl moiety and B is a moiety of the formula: ##STR2## The compounds are effective in potentiating the activity of chemotherapeutic anti-cancer agents by increasing the sensitivity of multi-drug resistant cells to such chemotherapeutic agents.
摘要翻译： 本文描述了其中R1，R2，R3，R4和R5的通式的化合物：A是直链或支链（C 2 -C 12）烷基或苯基部分，B是下式的部分： >这些化合物通过增加多药耐药性细胞对这种化学治疗剂的敏感性，有效地增强化疗抗癌药的活性。
-
公开(公告)号：US5387685A
公开(公告)日：1995-02-07
申请号：US92653
申请日：1993-07-16
申请人： Dennis Powell , Rolf Paul , William A. Hallett , Dan M. Berger , Minu D. Dutia
发明人： Dennis Powell , Rolf Paul , William A. Hallett , Dan M. Berger , Minu D. Dutia
IPC分类号： A61K31/40 , A61K31/403 , A61K31/4035 , A61K31/47 , A61K31/472 , A61K45/00 , A61P35/00 , A61P43/00 , C07C323/07 , C07C323/16 , C07C323/56 , C07C323/60 , C07D209/44 , C07D209/48 , C07D215/20 , C07D217/02 , C07D217/04 , C07D217/06 , C07D217/20 , C07D217/24 , C07D401/12 , C07D405/06 , C07D491/04 , C07D491/056 , C07D521/00 , C07F7/10 , C07F7/18 , C07D217/12
CPC分类号： C07D209/48 , C07C323/07 , C07C323/16 , C07C323/56 , C07C323/60 , C07D209/44 , C07D217/02 , C07D217/04 , C07D217/06 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D405/06 , C07D491/04 , C07F7/1856 , C07C2101/14
摘要： Compounds of the general formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are herein described, A is a straight or branched (C.sub.2 -C.sub.12)alkyl or a phenyl moiety and B is a moiety of the formula: ##STR2## The compounds are effective in potentiating the activity of chemotherapeutic anti-cancer agents by increasing the sensitivity of multi-drug resistant cells to such chemotherapeutic agents.
摘要翻译： 本文描述了其中R1，R2，R3，R4和R5的通式的化合物：A是直链或支链（C 2 -C 12）烷基或苯基部分，B是下式的部分： >这些化合物通过增加多药耐药性细胞对这种化学治疗剂的敏感性，有效地增强化疗抗癌药的活性。
-
公开(公告)号：US08378104B2
公开(公告)日：2013-02-19
申请号：US13025281
申请日：2011-02-11
申请人： Keith R. Hornberger , Dan M. Berger , Xin Chen , Andrew P. Crew , Hanqing Dong , Andrew Kleinberg , An-Hu Li , Lifu Ma , Mark J. Mulvihill , Bijoy Panicker , Kam W. Siu , Arno G. Steinig , James G. Tarrant , Jing Wang , Qinghua Weng , Rajaram Sangem , Ramesh C. Gupta
发明人： Keith R. Hornberger , Dan M. Berger , Xin Chen , Andrew P. Crew , Hanqing Dong , Andrew Kleinberg , An-Hu Li , Lifu Ma , Mark J. Mulvihill , Bijoy Panicker , Kam W. Siu , Arno G. Steinig , James G. Tarrant , Jing Wang , Qinghua Weng , Rajaram Sangem , Ramesh C. Gupta
IPC分类号： C07D471/02
CPC分类号： C07D491/048
摘要： Compounds of Formula 1, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by TAK1 or for which an appropriate TAK1 inhibitor is effective. This Abstract is not limiting of the invention.
摘要翻译： 式1的化合物，如下文所定义：其药学上可接受的盐，合成，中间体，制剂及其治疗方法，包括治疗癌症，例如至少部分由TAK1驱动的肿瘤，或适合于 TAK1抑制剂有效。 本发明并不限于本发明。
-
公开(公告)号：US5550149A
公开(公告)日：1996-08-27
申请号：US328643
申请日：1994-10-25
申请人： Dennis Powell , Rolf Paul , William A. Hallett , Dan M. Berger , Minu D. Dutia
发明人： Dennis Powell , Rolf Paul , William A. Hallett , Dan M. Berger , Minu D. Dutia
IPC分类号： A61K31/40 , A61K31/403 , A61K31/4035 , A61K31/47 , A61K31/472 , A61K45/00 , A61P35/00 , A61P43/00 , C07C323/07 , C07C323/16 , C07C323/56 , C07C323/60 , C07D209/44 , C07D209/48 , C07D215/20 , C07D217/02 , C07D217/04 , C07D217/06 , C07D217/20 , C07D217/24 , C07D401/12 , C07D405/06 , C07D491/04 , C07D491/056 , C07D521/00 , C07F7/10 , C07F7/18
CPC分类号： C07D209/48 , C07C323/07 , C07C323/16 , C07C323/56 , C07C323/60 , C07D209/44 , C07D217/02 , C07D217/04 , C07D217/06 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D405/06 , C07D491/04 , C07F7/1856 , C07C2101/14
摘要： Compounds of the general formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are herein described, A is a straight or branched (C.sub.2 -C.sub.12)alkyl or a phenyl moiety and B is a moiety of the formula: ##STR2## The compounds are effective in potentiating the activity of chemotherapeutic anti-cancer agents by increasing the sensitivity of multi-drug resistant cells to such chemotherapeutic agents.
-
公开(公告)号：US20120046267A1
公开(公告)日：2012-02-23
申请号：US13025281
申请日：2011-02-11
申请人： Keith R. Hornberger , Dan M. Berger , Xin Chen , Andrew P. Crew , Hanqing Dong , Andrew Kleinberg , An-Hu Li , Lifu Ma , Mark J. Mulvihill , Bijoy Panicker , Kam W. Siu , Arno G. Steinig , James G. Tarrant , Jing Wang , Qinghua Weng , Rajaram Sangem , Ramesh C. Gupta
发明人： Keith R. Hornberger , Dan M. Berger , Xin Chen , Andrew P. Crew , Hanqing Dong , Andrew Kleinberg , An-Hu Li , Lifu Ma , Mark J. Mulvihill , Bijoy Panicker , Kam W. Siu , Arno G. Steinig , James G. Tarrant , Jing Wang , Qinghua Weng , Rajaram Sangem , Ramesh C. Gupta
IPC分类号： A61K31/4355 , A61K31/4545 , A61K31/4725 , A61K31/4709 , A61K31/5377 , C07D495/04 , A61K31/4365 , A61K31/519 , A61K31/5025 , C07D513/04 , A61K31/437 , C07D487/04 , A61K31/4985 , A61K31/502 , C12N9/99 , A61P35/00 , A61P29/00 , C07D491/048
CPC分类号： C07D491/048
摘要： Compounds of Formula 1, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by TAK1 or for which an appropriate TAK1 inhibitor is effective. This Abstract is not limiting of the invention.
摘要翻译： 式1的化合物，如下文所定义：其药学上可接受的盐，合成，中间体，制剂及其治疗方法，包括治疗癌症，例如至少部分由TAK1驱动的肿瘤，或适合于 TAK1抑制剂有效。 本发明并不限于本发明。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.062 秒)
